| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
 
																	On January 17, 2023, the parties received written notice from CFIUS that it had determined that there were no unresolved nation...
 
																	As previously disclosed, on October 18, 2022, AVEO Pharmaceuticals, Inc., a Delaware corporation (“AVEO”), entered into an Agre...
 
																	AVEO Oncology ("AVEO") (NASDAQ:AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to deliv...
 
																	-SEC Filing
 
																	https://www.scribd.com/document/609450380/Aveo-Patent
 
																	Upgrades
 
																	Within the last quarter, AVEO Pharmaceuticals (NASDAQ:AVEO) has observed the following analyst ratings:
 
																	Stifel analyst Stephen Willey downgrades AVEO Pharmaceuticals (NASDAQ:AVEO) from Buy to Hold and announces $15 price target.
 
																	AVEO Pharmaceuticals (NASDAQ:AVEO) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of ...